Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study

BACKGROUND AND AIM: Cardiotoxicity has become the most common cause of non-cancer death among breast cancer patients. Pyrotinib, a tyrosine kinase inhibitor targeting HER2, has been successfully used to treat breast cancer patients but has also resulted in less well-understood cardiotoxicity. This p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Yezi, Jiang, Meng, Wang, Yaohui, Liu, Qiming, Lu, Qifan, Tao, Zhengyu, Wu, Qizhen, Yin, Wenjin, Lu, Jinsong, Pu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950570/
https://www.ncbi.nlm.nih.gov/pubmed/36844736
http://dx.doi.org/10.3389/fcvm.2023.1021937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950570/
https://www.ncbi.nlm.nih.gov/pubmed/36844736
http://dx.doi.org/10.3389/fcvm.2023.1021937

Ejemplares similares